Beltran Pedro 4

What Happened

• Pedro Beltran, Chief Scientific Officer of BridgeBio Oncology Therapeutics, Inc. (BBOT), was granted a total of 256,670 equity awards on 2026-03-10. The awards consist of 46,670 RSUs and 210,000 derivative awards (options or other equity-based units). All awards were granted at $0 per share (no cash paid). These are grants/awards (not open-market purchases or sales) and will vest over time per the schedules below.

Key Details

• Transaction date: March 10, 2026; Form 4 filed March 12, 2026 (timely filing).
• Grants: 46,670 RSUs (F1) and 210,000 derivative awards (F2); total = 256,670 shares/units; grant price reported as $0.00.
• Vesting:
  • RSUs (F1): Vest in 16 equal quarterly installments over four years starting Jan 1, 2026; settled in shares upon vesting.
  • Derivative award (F2): Vests 1/48th monthly beginning Jan 1, 2026 (monthly installments over four years).
• Shares owned after transaction: Not disclosed in the Form 4.
• Filing status: Not marked late; appears filed within the required two-business-day window.
• Nature of transaction code: "A" = Award/Grant (routine equity compensation, not a sale or purchase).

Context

• RSUs and the derivative award will convert to or allow acquisition of common shares only as they vest; there was no immediate sale or cashless exercise reported. Such grants are standard executive compensation and do not by themselves indicate an immediate bullish or bearish signal.